Grant Matthew Fischer, M.D.,Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Histiocytoma, Malignant Fibrous | 1 | 2023 | 63 | 0.870 |
Why?
|
| Skin Neoplasms | 4 | 2023 | 5686 | 0.870 |
Why?
|
| Glomus Tumor | 1 | 2023 | 66 | 0.860 |
Why?
|
| Melanoma | 8 | 2023 | 5510 | 0.830 |
Why?
|
| Herpesvirus 8, Human | 1 | 2023 | 258 | 0.780 |
Why?
|
| Sarcoma, Kaposi | 1 | 2023 | 370 | 0.720 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2020 | 424 | 0.690 |
Why?
|
| Precancerous Conditions | 1 | 2022 | 975 | 0.530 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2019 | 1038 | 0.450 |
Why?
|
| Oxidative Phosphorylation | 3 | 2020 | 481 | 0.330 |
Why?
|
| Tumor Microenvironment | 3 | 2020 | 3586 | 0.300 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2022 | 4034 | 0.290 |
Why?
|
| Brain Neoplasms | 4 | 2021 | 8863 | 0.270 |
Why?
|
| Focal Adhesion Protein-Tyrosine Kinases | 2 | 2019 | 182 | 0.270 |
Why?
|
| Oxadiazoles | 2 | 2020 | 93 | 0.230 |
Why?
|
| Glutaminase | 1 | 2020 | 35 | 0.190 |
Why?
|
| DNA Fingerprinting | 1 | 2021 | 112 | 0.190 |
Why?
|
| Phosphoglycerate Dehydrogenase | 1 | 2020 | 38 | 0.190 |
Why?
|
| Gene Fusion | 1 | 2023 | 371 | 0.180 |
Why?
|
| Scalp | 1 | 2022 | 380 | 0.180 |
Why?
|
| Databases, Nucleic Acid | 1 | 2020 | 211 | 0.170 |
Why?
|
| Molecular Biology | 1 | 2023 | 596 | 0.170 |
Why?
|
| Tissue Array Analysis | 1 | 2020 | 553 | 0.160 |
Why?
|
| HIV Infections | 1 | 2023 | 16718 | 0.140 |
Why?
|
| Piperidines | 2 | 2020 | 1602 | 0.130 |
Why?
|
| Neoplasms, Second Primary | 1 | 2023 | 1061 | 0.120 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2020 | 3557 | 0.120 |
Why?
|
| Amino Acid Substitution | 1 | 2019 | 1791 | 0.120 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2023 | 1861 | 0.110 |
Why?
|
| Gene Expression Profiling | 2 | 2020 | 9438 | 0.110 |
Why?
|
| Mice, Nude | 1 | 2019 | 3689 | 0.100 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 1 | 2013 | 188 | 0.100 |
Why?
|
| Metabolome | 1 | 2019 | 895 | 0.100 |
Why?
|
| MAP Kinase Signaling System | 1 | 2019 | 1526 | 0.100 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2021 | 8428 | 0.100 |
Why?
|
| Up-Regulation | 1 | 2020 | 4217 | 0.100 |
Why?
|
| Tumor Cells, Cultured | 1 | 2019 | 6314 | 0.100 |
Why?
|
| Sequence Analysis, RNA | 1 | 2019 | 2012 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2019 | 2503 | 0.090 |
Why?
|
| Myocytes, Smooth Muscle | 1 | 2013 | 687 | 0.080 |
Why?
|
| Lung Neoplasms | 2 | 2023 | 13102 | 0.070 |
Why?
|
| Humans | 15 | 2023 | 744343 | 0.070 |
Why?
|
| Immunohistochemistry | 1 | 2020 | 11366 | 0.070 |
Why?
|
| Mice | 8 | 2021 | 81183 | 0.070 |
Why?
|
| Neoplasm Transplantation | 2 | 2021 | 2085 | 0.070 |
Why?
|
| Animals | 9 | 2021 | 168757 | 0.070 |
Why?
|
| Actins | 1 | 2013 | 2121 | 0.060 |
Why?
|
| Genomics | 1 | 2021 | 5720 | 0.060 |
Why?
|
| Disease Models, Animal | 2 | 2020 | 18029 | 0.060 |
Why?
|
| Geriatric Assessment | 1 | 2011 | 1372 | 0.060 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2023 | 11524 | 0.060 |
Why?
|
| Transcription Factors | 1 | 2023 | 12208 | 0.060 |
Why?
|
| Cell Line, Tumor | 4 | 2020 | 16689 | 0.060 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2019 | 5535 | 0.060 |
Why?
|
| T-Lymphocytes | 1 | 2020 | 10180 | 0.060 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2013 | 2948 | 0.050 |
Why?
|
| Female | 7 | 2023 | 380194 | 0.050 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2020 | 5221 | 0.050 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2020 | 5172 | 0.050 |
Why?
|
| Mice, Inbred C57BL | 1 | 2019 | 21827 | 0.050 |
Why?
|
| Prognosis | 1 | 2020 | 29063 | 0.040 |
Why?
|
| Protein Array Analysis | 1 | 2021 | 411 | 0.040 |
Why?
|
| Superoxide Dismutase | 1 | 2021 | 597 | 0.040 |
Why?
|
| Mutation | 1 | 2022 | 29786 | 0.040 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2020 | 730 | 0.040 |
Why?
|
| Proteomics | 2 | 2021 | 3638 | 0.040 |
Why?
|
| Antineoplastic Agents | 1 | 2020 | 13695 | 0.040 |
Why?
|
| Glycine | 1 | 2020 | 671 | 0.040 |
Why?
|
| Cognition Disorders | 1 | 2011 | 4043 | 0.040 |
Why?
|
| Serine | 1 | 2020 | 826 | 0.040 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2021 | 2505 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2019 | 40561 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2020 | 1655 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2021 | 2716 | 0.030 |
Why?
|
| Mass Screening | 1 | 2011 | 5255 | 0.030 |
Why?
|
| Signal Transduction | 1 | 2017 | 23403 | 0.030 |
Why?
|
| DNA Copy Number Variations | 1 | 2023 | 1941 | 0.030 |
Why?
|
| Brain | 1 | 2020 | 26385 | 0.030 |
Why?
|
| Protein Kinases | 1 | 2019 | 1640 | 0.030 |
Why?
|
| Aged | 2 | 2022 | 163280 | 0.030 |
Why?
|
| Metabolomics | 1 | 2020 | 1484 | 0.030 |
Why?
|
| Overweight | 1 | 2023 | 2371 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2019 | 3616 | 0.020 |
Why?
|
| Cell Survival | 1 | 2021 | 5882 | 0.020 |
Why?
|
| Mental Status Schedule | 1 | 2011 | 321 | 0.020 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2019 | 2109 | 0.020 |
Why?
|
| Hyperplasia | 1 | 2013 | 1185 | 0.020 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2019 | 2043 | 0.020 |
Why?
|
| Base Sequence | 1 | 2021 | 12797 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2019 | 8436 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2021 | 10252 | 0.020 |
Why?
|
| Protein Transport | 1 | 2013 | 1988 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2013 | 3701 | 0.020 |
Why?
|
| Male | 2 | 2023 | 350118 | 0.020 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2020 | 4479 | 0.020 |
Why?
|
| Mitochondria | 1 | 2019 | 3520 | 0.020 |
Why?
|
| Reactive Oxygen Species | 1 | 2013 | 2077 | 0.020 |
Why?
|
| Immunotherapy | 1 | 2020 | 4445 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2023 | 12720 | 0.020 |
Why?
|
| Cell Nucleus | 1 | 2013 | 2969 | 0.010 |
Why?
|
| Positron-Emission Tomography | 1 | 2019 | 6234 | 0.010 |
Why?
|
| Cell Movement | 1 | 2013 | 5217 | 0.010 |
Why?
|
| Obesity | 1 | 2023 | 12745 | 0.010 |
Why?
|
| Caregivers | 1 | 2011 | 2094 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2013 | 14557 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2013 | 10481 | 0.010 |
Why?
|
| Models, Biological | 1 | 2013 | 9583 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2023 | 63114 | 0.010 |
Why?
|
| Risk Factors | 1 | 2023 | 72290 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2011 | 14722 | 0.010 |
Why?
|
| Phenotype | 1 | 2013 | 16365 | 0.010 |
Why?
|
| Emergency Service, Hospital | 1 | 2011 | 7659 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2011 | 25043 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2011 | 53288 | 0.000 |
Why?
|
| Aged, 80 and over | 1 | 2011 | 57776 | 0.000 |
Why?
|